Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Patent
1994-03-17
1998-01-20
Nucker, Christine M.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
530328, 4241891, 4242281, C12Q 170, A61K 3804, A61K 3929
Patent
active
057099952
ABSTRACT:
The hepatitis C virus (HCV) is the major cause of non-A, non-B vital hepatitis. The most striking feature of HCV induced liver disease is its tendency toward chronicity and slowly progressive liver cell injury. HLA Class I-restricted cytotoxic T lymphocyte (CTL) responses are considered to be a sine qua non for the effective clearance of vital infections. However, the characteristics of HCV-specific cytotoxic effector cells and identification of their cognate target antigens remains to be elucidated. This invention discloses novel HCV-derived peptides that are recognized by patient CTL. Peripheral blood mononuclear cells (PBMC) were obtained from HLA-A2 positive patients with chronic HCV infection and stimulated with HCV-derived peptides. Effector cells were tested for their ability to lyse HLA-A2-matched target cells sensitized either with a peptide or a vaccinia virus construct containing HCV sequences. Immunogenic HCV CTL peptides were identified in the putative core protein and nonstructural proteins (e.g., NS3-5). These peptides have the following amino acid sequences: ADLMGYIPLV (Core.sub.131-140), LLALLSCLTV (Core.sub.178-187), QLRRHIDLLV (E1.sub.257-266) , LLCPAGHAV (NS3.sub.1169-1177), KLVALGINAV (NS3.sub.1406-1415), SLMAFTAAV (NS4.sub.1789-1797) , LLFNILGGWV (NS4.sub.1807-1816), ILDSFDPLV (NS5.sub.2252-2260), and DMLGYIPLV (Core.sub.132-140). These peptides facilitate the stimulation and identification of HCV-specific CTL and should provide useful diagnostic reagents for the detection of HCV infection.
REFERENCES:
patent: 4565697 (1986-01-01), Ohmura et al.
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4625918 (1986-12-01), Hershberg
patent: 4690915 (1987-09-01), Rosenberg
patent: 4803164 (1989-02-01), Hitzeman et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 4977092 (1990-12-01), Bitter
patent: 5017558 (1991-05-01), Vyas
patent: 5019386 (1991-05-01), Machida et al.
patent: 5106726 (1992-04-01), Wang
patent: 5196512 (1993-03-01), Bianchi et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
Aichele et al., "Antiviral Cytotoxic T Cell Response Induced by In Vivo Priming with a Free Synthetic Peptide," J. Exp. Med, 171, 1815-1820 (1990).
Allen et al., "Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope," Nature 327, 713-715 (1987).
Alter, "Epidemiology of Community-acquired Hepatitis C," Viral Hepatitis and Liver Disease, pp. 410-413 (Hollinger et al., eds. (1991)).
Bukh et al., "Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay," Proc. Natl. Acad. Sci. USA, 187-191 (1992).
Carbone et al., "Induction of Cytotoxic T Lymphocytes by Primary In Vivo Stimulation with Peptides," J. Exp. Med., 167, 1767-1779 (1988).
Cheng et al., "Hepatitis B Virus Large Surface Protein Is Not Secreted but Is Immunogenic when Selectively Expressed by Recombinant Vaccinia Virus," J. Virol., 60, 337-344 (1986).
Choo et al., "Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome," Science, 244, 337-334 (1989).
Choo et al., "Genetic organization and diversity of the hepatitis C virus," Proc. Natl. Acad. Sci. USA, 88, 2451-2455 (1991).
Clerici et al., "Detection of Cytotoxic T Lymphocytes Specific for Synthetic Peptides of gp160 in HIV-Seropositive Individuals," J. Imm. 146, 2214-2219 (1991).
Deres et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," Nature, 342, 561-564 (1989).
Dienstag, "Non-B Hepatitis. I. Recognition, Epidemiology,, and Clinical Features," Gastroenterology, 85, 439-462 (1983).
Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature, 351, 290-296 (1991).
Guo et al., "Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle," Nature, 360, 364-366 (1992).
Harty et al., "CD8+ T Cells Specific for a Single Nonamer Epitope of Listeria monocytogenes Are Protective In Vivo," J. Exp. Med., 175, 1531-1538 (1992).
Houghton et al., "Molecular Biology of the Hepatitis C Viruses: Implications for Diagnosis, Development and Control of Viral Disease," Hepatology, 14, 381-388 (1991).
Jansen et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62, 185-216 (1982).
Jardetzky et al., "Identification of self peptides bound to purified HLA-B27," Nature, 353, 326-329 (1991).
Kast et al., "Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," Proc. Natl. Acad. Sci. USA, 2283-2287 (1991).
Koziel et al., "Intrahepatic Cytotoxic T Lymphocytes Specific for Hepatitis C Virus in Persons with Chronic Hepatitis," J. Imunol., 149, 3339-3334 (1992).
Lenzi et al., "Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity," Lancet, 338, 277-280 (1991).
Maryanski et al., "Competitor Analogs fof Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers," Cell, 60, 63-72 (1990).
Monaco, "A molecular model of MHC class-I-restricted antigen processing," Immunol. Today, 13, 173-179 (1992).
Mondelli et al., "Does the Immune Response Play a Role in the Pathogenesis of Chronic Liver Disease?", Arch. Pathol. Lab. Med., 112, 489-497 (1988).
Okamoto et al., "Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources," J. Gen. Virol., 73, 673-679 (1992).
Roitt et al., Immunology, 3d ed., 15.3-15.4 (1993).
Rothbard et al., "Interactions Between Immunogenic Peptides and MHC Proteins," Ann. Rev. Immunol., 9, 527-565 (1991).
Rotzschke et al., "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," Nature, 348, 252-254 (1990).
Rotzschke et al., "Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway," Immunol. Today, 12, 447-455 (1991).
Schumacher et al., "Peptide selectioin by MHC class I molecules," Nature, 350, 703-706 (1991).
Sette et al., "Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells," Nature, 328, 395-399 (1987).
Takahashi et al., "Structural Requirements for Class I MHC Molecule-Mediated Antigen Presentation and Cytotoxic T Cell Recognition of an Immunodominant Determination of the Human Immunodeficiency Virus Envelope Protein," J. Exp. Med., 170, 2023-2035 (1989).
Van Bleek et al., "Isolation of an endogenously processed immunodominant viral peptide from the class I H-2k.sup.b molecule," Nature, 348, 213-216 (1990).
Hahn et al., 1992, CD8+ T cell recognition of an endogenously processed epitope is regulated primarily be residues within the epitope, J. Exp. Med. 176:1335-1341.
Eisenlohr et al., 1992, Flanking sequenced influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes, J. Exp. Med. 175:481-487.
Del Val et al., 1991, Efficient processing of an antigenic sequence for presentation by MHC Class I molecules depends on its neighboring residues in the protein, Cell 66:1145-1153.
Hansen et al., 1993, The major histocompatibility complex, in Fundamental Immunology, Paul, ed., Raven Press, New York, NY pp. 577-628.
Koziel et al., 1993, Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize eptitopes in the core and envelope proteins of HCV, J. Virol., 67(12):7522-7532.
Monaco, J., 1992, A molecular model of MHC class-I-restricted antigen processing, Immunol. Today 13(5):173-179.
Kita et al., 1993, HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein, Hepatol. 18(5):1039-1044.
Reece et al., 1993, Mapping the major human T helper epitopes of tetanus toxin, J. Immunol. 151:6175-6184.
Shirai et al., 1992, Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with mult
Cerny Andreas
Chisari Francis V.
Nucker Christine M.
Parkin Jeffrey S.
The Scripps Research Institute
LandOfFree
Hepatitis C virus-derived peptides capable of inducing cytotoxic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus-derived peptides capable of inducing cytotoxic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus-derived peptides capable of inducing cytotoxic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-724329